BioCentury
ARTICLE | Finance

CAR talk

Why investors in Kite, Juno won't see near-term CAR T data in solid tumors

April 27, 2015 7:00 AM UTC

While investors in Kite Pharma Inc. (NASDAQ:KITE) and Juno Therapeutics Inc. (NASDAQ:JUNO) will soon be combing through American Society of Clinical Oncology abstracts, they shouldn't hold their breath for efficacy data for the CAR T companies' solid tumor programs.

Many investors are hungry for such data because they think it's hard to justify the valuations of CAR T companies based on results in hematological malignancies alone. ...